Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.

Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.
复制标题

DOI:
10.1016/j.mce.2013.09.004
复制
发表时间:
2014-04-05
影响因子:
4.1
通讯作者:
Berryman DE
Berryman DE
中科院分区:
医学2区
文献类型:
--
作者:
Kopchick JJ;List EO;Kelder B;Gosney ES;Berryman DE

文献摘要

参考文献

被引文献

相似文献

生长激素受体拮抗剂(GHA)的发现最初是通过在转基因小鼠中表达突变的GH基因而建立的。在这一发现之后,该化合物的开发导致了一种名为pegvisomant的药物,该药物已被批准用于肢端肥大症患者。在大多数患者中,以剂量依赖性方式进行的Pegvisomant治疗导致IGF-1水平正常化。因此,它是一种非常有效和安全的药物。由于GH/IGF-1轴与几种类型癌症的进展有关,许多人建议使用pegvisomant作为抗癌治疗剂。在这篇手稿中,我们将审查使用小鼠品系,具有升高或降低水平的GH行动解开许多GH行动。此外,我们还将描述发现GHA的实验,回顾pegvisomant的临床前和临床试验结果,并提供表明pegvisomant在选定类型的癌症中的治疗价值的数据。
The discovery of a growth hormone receptor antagonist (GHA) was initially established via expression of mutated GH genes in transgenic mice. Following this discovery, development of the compound resulted in a drug termed pegvisomant, which has been approved for use in patients with acromegaly. Pegvisomant treatment in a dose dependent manner results in normalization of IGF-1 levels in most patients. Thus, it is a very efficacious and safe drug. Since the GH/IGF-1 axis has been implicated in the progression of several types of cancers, many have suggested the use of pegvisomant as an anti-cancer therapeutic. In this manuscript, we will review the use of mouse strains that possess elevated or depressed levels of GH action for unraveling many of GH actions. Additionally, we will describe experiments in which the GHA was discovered, review results of pegvisomant’s preclinical and clinical trials, and provide data suggesting pegvisomant’s therapeutic value in selected types of cancer.
生长激素受体的破坏可防止卡路里的限制改善胰岛素作用和寿命。
DOI: 10.1371/journal.pone.0004567
发表时间: 2009
期刊: PloS one
影响因子: 3.7
作者:
Bonkowski MS;Dominici FP;Arum O;Rocha JS;Al Regaiey KA;Westbrook R;Spong A;Panici J;Masternak MM;Kopchick JJ;Bartke A
通讯作者: Bartke A
DOI: 10.1210/en.2003-0374
发表时间: 2003-09-01
期刊: ENDOCRINOLOGY
影响因子: 4.8
作者:
Coschigano, KT;Holland, AN;Kopchick, JJ
通讯作者: Kopchick, JJ
DOI: 10.1210/jc.2005-0331
发表时间: 2005-10-01
影响因子: 5.8
作者:
Barkan, AL;Burman, P;Vance, ML
通讯作者: Vance, ML
DOI: 10.1126/science.2466339
发表时间: 1989-03-10
期刊: SCIENCE
影响因子: 56.9
作者:
CUNNINGHAM, BC;JHURANI, P;WELLS, JA
通讯作者: WELLS, JA
DOI: 10.1210/en.2004-1120
发表时间: 2005-02-01
期刊: ENDOCRINOLOGY
影响因子: 4.8
作者:
Al-Regaiey, KA;Masternak, MM;Bartke, A
通讯作者: Bartke, A